Maureen Dubreuil, MD, MSc.

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Dubreuil is a rheumatologist in Boston, specializing in spondyloarthritis. She works within the Rheumatology section at Chobanian and Avedisian School of Medicine, where her research focuses on comorbidities and pharmacoepidemiology of spondyloarthritis. Dr. Dubreuil's research has been funded by numerous competitive grants from funders including the NIH, private foundations and industry. Some highlights of Dr. Dubreuil's work includes:
1. Discovery of two key protective effects of TNF inhibitors against fractures and cardiovascular events in spondyloarthritis
2. Finding that a common nonsteroidal anti-inflammatory drug is associated with 3 times the risk of heart attack among people with spondyloarthritis
3. Development of the first North American guidelines for referral of adults at increased risk of having spondyloarthritis to a rheumatologist

In addition to her research, Dr. Dubreuil is a member of the leading international organizations for spondyloarthritis research. She serves on the Executive Committee of the Board of Directors for the Spondyloarthritis Research and Treatment Network, and on the Medical Advisory Board for the Spondylitis Association of America. She is a site investigator for the international CLASSIC study in spondyloarthritis. Dr. Dubreuil is the Director of Research Training for the Rheumatology Fellowship program at Boston Medical Center.

Dr. Dubreuil cares for people with rheumatic conditions at Boston Medical Center and the VA Boston Healthcare System. Dr. Dubreuil's patients say the following about her:
"Dr. Dubreuil is a very caring and knowledgeable doctor and it's always a pleasure to be seen by her."
"I am very satisfied with the care I have received. My provider and the support staff is very professional, caring and concerned. I would recommend to anyone."
"Dr. Dubreuil is a gem and I feel so lucky to have her!"
A survey of 40 patients who received care by Dr. Dubreuil in 2024-2025 found that 100% would recommend her!

Publications

  • Published 9/22/2025

    Degirmenci HB, Peloquin CE, Westerland M, Lodi S, Machado PM, Jafarzadeh SR, Neogi T, Gensler LS, Dubreuil M, Liew JW. Trends in Opioid Prescriptions in Individuals with Axial Spondyloarthritis in the US and UK in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data. Arthritis Care Res (Hoboken). 2025 Sep 22. PMID: 40977482.

    Read at: PubMed

  • Published 9/11/2025

    Achkar A, Peloquin C, Liew JW, Dubreuil M. Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis. Clin Rheumatol. 2025 Sep 11. PMID: 40936006.

    Read at: PubMed

  • Published 6/1/2025

    Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Hughes GC, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N. Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 Jun 01; 64(6):3434-3443. PMID: 39936579.

    Read at: PubMed

  • Published 4/28/2025

    Neogi T, Dubreuil M, Peloquin C, Marinko L, Camarinos J, Felson DT, Kumar D. Reply. Arthritis Rheumatol. 2025 Apr 28. PMID: 40289862.

    Read at: PubMed

  • Published 4/2/2025

    Neogi T, Dubreuil M, Peloquin C, Marinko L, Camarinos J, Felson DT, Kumar D. Association of Physical Therapy Care With Use of Intra-Articular Injections in People With Knee Osteoarthritis: A Real-World Cohort Study. Arthritis Rheumatol. 2025 Aug; 77(8):1006-1014. PMID: 40091450.

    Read at: PubMed